{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Adenosquamous+Carcinoma+of+the+Pancreas", "query": { "condition": "Adenosquamous Carcinoma of the Pancreas" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 14, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Adenosquamous+Carcinoma+of+the+Pancreas&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-06-10T10:47:50.238Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06115499", "title": "The PLATINUM Trial: Optimizing Chemotherapy for the Second-Line Treatment of Metastatic BRCA1/2 or PALB2-Associated Metastatic Pancreatic Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Pancreatic Acinar Cell Carcinoma", "Pancreatic Adenocarcinoma", "Pancreatic Adenosquamous Carcinoma", "Pancreatic Carcinoma", "Pancreatic Ductal Adenocarcinoma", "Pancreatic Squamous Cell Carcinoma", "Stage IV Pancreatic Cancer AJCC v8" ], "interventions": [ { "name": "Nab paclitaxel", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2024-08-13", "completion_date": "2029-12-09", "has_results": false, "last_update_posted_date": "2026-01-07", "last_synced_at": "2026-06-10T10:47:50.238Z", "location_count": 345, "location_summary": "Anchorage, Alaska • Goodyear, Arizona • Phoenix, Arizona + 253 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT06115499" }, { "nct_id": "NCT07621718", "title": "Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pancreatic Cancer", "Pancreatic Cancer Metastatic", "PDAC", "PDAC - Pancreatic Ductal Adenocarcinoma", "Pancreatic Ductal Adenocarcinoma (PDAC)", "Pancreatic Adenocarcinoma Metastatic", "Pancreatic Adenocarcinoma", "Pancreatic Adenosquamous Carcinoma" ], "interventions": [ { "name": "Zoldonrasib", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Leucovorin (Calcium Folinate)", "type": "DRUG" }, { "name": "5-Fluorouracil", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "Gemcitabine (GEM)", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Revolution Medicines, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 670, "start_date": "2026-05-22", "completion_date": "2030-04-22", "has_results": false, "last_update_posted_date": "2026-06-02", "last_synced_at": "2026-06-10T10:47:50.238Z", "location_count": 1, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT07621718" }, { "nct_id": "NCT04340141", "title": "Testing the Use of the Usual Chemotherapy Before and After Surgery for Removable Pancreatic Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pancreatic Adenosquamous Carcinoma", "Resectable Pancreatic Adenocarcinoma", "Pancreatic Cancer" ], "interventions": [ { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Irinotecan Hydrochloride", "type": "DRUG" }, { "name": "Leucovorin Calcium", "type": "DRUG" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Resection", "type": "PROCEDURE" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "DRUG", "PROCEDURE", "OTHER" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 358, "start_date": "2020-10-13", "completion_date": "2030-11-01", "has_results": false, "last_update_posted_date": "2026-02-10", "last_synced_at": "2026-06-10T10:47:50.238Z", "location_count": 441, "location_summary": "Birmingham, Alabama • Fairhope, Alabama • Mobile, Alabama + 325 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Fairhope", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT04340141" }, { "nct_id": "NCT04116073", "title": "INCMGA00012 in Patients With Previously Treated Unresectable or Metastatic Adenosquamous Pancreatic or Ampullary Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pancreatic Cancer Non-resectable", "Pancreatic Cancer Metastatic" ], "interventions": [ { "name": "INCMGA00012 (PD-1 antibody)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2020-04-09", "completion_date": "2024-12-03", "has_results": true, "last_update_posted_date": "2025-07-29", "last_synced_at": "2026-06-10T10:47:50.238Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04116073" }, { "nct_id": "NCT05988918", "title": "Multicenter Trial of ESK981 in Patients With Select Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pancreatic Adenocarcinoma", "Adenosquamous Carcinoma", "Pancreatic Neuroendocrine Tumor", "Pancreatic Neuroendocrine Carcinoma", "Gastrointestinal Neuroendocrine Tumor", "Gastrointestinal Neuroendocrine Carcinoma", "Neuroendocrine Prostate Carcinoma" ], "interventions": [ { "name": "ESK981", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Michigan Rogel Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 17, "start_date": "2024-04-19", "completion_date": "2027-08", "has_results": false, "last_update_posted_date": "2026-05-14", "last_synced_at": "2026-06-10T10:47:50.238Z", "location_count": 2, "location_summary": "Ann Arbor, Michigan • Madison, Wisconsin", "locations": [ { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT05988918" }, { "nct_id": "NCT07491445", "title": "Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pancreatic Cancer", "Pancreatic Cancer Metastatic", "PDAC", "PDAC - Pancreatic Ductal Adenocarcinoma", "Pancreatic Ductal Adenocarcinoma (PDAC)", "Pancreatic Adenocarcinoma Metastatic", "Pancreatic Adenocarcinoma", "Pancreatic Adenosquamous Carcinoma" ], "interventions": [ { "name": "daraxonrasib", "type": "DRUG" }, { "name": "gemcitabine", "type": "DRUG" }, { "name": "nab-paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Revolution Medicines, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 900, "start_date": "2026-03-09", "completion_date": "2029-03", "has_results": false, "last_update_posted_date": "2026-06-03", "last_synced_at": "2026-06-10T10:47:50.238Z", "location_count": 5, "location_summary": "Baltimore, Maryland • Boston, Massachusetts • Henderson, Nevada + 2 more", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Henderson", "state": "Nevada" }, { "city": "Maumee", "state": "Ohio" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT07491445" }, { "nct_id": "NCT04858334", "title": "APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pancreatic Acinar Cell Carcinoma", "Pancreatic Adenosquamous Carcinoma", "Pancreatic Squamous Cell Carcinoma", "Resectable Pancreatic Acinar Cell Carcinoma", "Resectable Pancreatic Adenocarcinoma", "Resectable Pancreatic Adenosquamous Carcinoma", "Resectable Pancreatic Carcinoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Olaparib", "type": "DRUG" }, { "name": "Placebo Administration", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 152, "start_date": "2021-06-22", "completion_date": "2027-10-31", "has_results": false, "last_update_posted_date": "2026-06-03", "last_synced_at": "2026-06-10T10:47:50.238Z", "location_count": 451, "location_summary": "Anchorage, Alaska • Fairbanks, Alaska • Kingman, Arizona + 303 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT04858334" }, { "nct_id": "NCT04157127", "title": "Th-1 Dendritic Cell Immunotherapy Plus Standard Chemotherapy for Pancreatic Adenocarcinoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pancreatic Adenocarcinoma", "Pancreatic Cancer", "Pancreatic Adenosquamous Carcinoma" ], "interventions": [ { "name": "Autologous DC Therapy", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Diakonos Oncology Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2020-08-03", "completion_date": "2027-12", "has_results": false, "last_update_posted_date": "2025-05-25", "last_synced_at": "2026-06-10T10:47:50.238Z", "location_count": 3, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04157127" }, { "nct_id": "NCT05194735", "title": "Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Gynecologic Cancer", "Colorectal Cancer", "Pancreatic Cancer", "Non-small Cell Lung Cancer", "Cholangiocarcinoma", "Ovarian Cancer", "Endometrial Cancer", "Ovarian Carcinoma", "Ovary Neoplasm", "Squamous Cell Lung Cancer", "Adenocarcinoma of Lung", "Adenosquamous Cell Lung Cancer" ], "interventions": [ { "name": "Neoantigen specific TCR-T cell drug product", "type": "BIOLOGICAL" }, { "name": "Aldesleukin (IL-2)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Alaunos Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 8, "start_date": "2022-04-04", "completion_date": "2023-08-14", "has_results": true, "last_update_posted_date": "2025-11-10", "last_synced_at": "2026-06-10T10:47:50.238Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05194735" }, { "nct_id": "NCT05292859", "title": "Long-Term Follow-up Study of Subjects Treated With Autologous T Cells Using the Sleeping Beauty System to Express TCRs", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Gynecologic Cancer", "Colorectal Cancer", "Pancreatic Cancer", "Non-small Cell Lung Cancer", "Cholangiocarcinoma", "Ovarian Cancer", "Ovary Neoplasm", "Squamous Cell Lung Cancer", "Adenocarcinoma of Lung", "Adenosquamous Cell Lung Cancer" ], "interventions": [ { "name": "Neoantigen specific TCR-T cell drug product", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Alaunos Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 7, "start_date": "2023-03-01", "completion_date": "2025-05-30", "has_results": false, "last_update_posted_date": "2025-07-30", "last_synced_at": "2026-06-10T10:47:50.238Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05292859" } ] }